Maci (matrix-applied characterised autologous cultured chondrocytes)
ATMP
- Region
- 🇪🇺 EU
- Active substance
- matrix-applied characterised autologous cultured chondrocytes
- Company
- Vericel Denmark ApS
- Status
- Expired
- Therapeutic area
- Fractures, Cartilage
- EU approval
- Thu 27 Jun 2013
- Designations
- ATMP
- Application
- EMEA/H/C/002522
- ATC
- M09AX02
- Official record
- www.ema.europa.eu
Indication
Repair of symptomatic cartilage defects of the knee.
Regulatory milestones
No milestones recorded in the last year.
Follow Maci
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.